Wednesday, July 8, 2026

pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

Talon Biomarkers

Talon Biomarkers clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Whippany, USA HQ
2021 Founded
7 Employees
PMDA registrant Type
Company details
Status
Public
HQ
Whippany, USA
Founded
2021
Employees
7
Programs
5
Drugs
44
Patents
0
Intelligence · Clinical Programs

Talon Biomarkers projects

2 ClinicalTrials.gov programs sponsored by Talon Biomarkers.

Talon Biomarkers has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PRIN - 20227EA9AN

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial
  2. PRIN - 20227EA9AN

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Talon Biomarkers have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.